Sana Biotechnology, Inc. SANA

Rank #1970 · Nasdaq · $0.7B market cap

⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

37.6

P/E

-2.5

P/B

1.43

ROE

-56.7%

Op. Margin

–%

Debt Ratio

50%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -2.5x, P/B 1.43x. Ranks in the top 59% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -56.7%. Ranks in the top 90% of the universe.

Safety ★★★★☆

Good

Debt ratio 50%. Ranks in the top 23% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2021	–	$-0.1B	$-0.1B	$-0.0B	–	-2264
2022	–	$-0.3B	$-0.3B	$-0.1B	–	-281
2023	–	$-0.4B	$-0.4B	$-0.4B	–	-77
2024	–	$-0.3B	$-0.3B	$0.7B	–	38
2025	–	$-0.3B	$-0.3B	$0.5B	–	50

← See the full screener